Joseph A. Fraietta

California University of Pennsylvania — United States

Medicine · Health Sciences

45h-index15.3kcitations350works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(265), Viral Infectious Diseases and Gene Expression in Insects(57), Immune Cell Function and Interaction(53), CRISPR and Genetic Engineering(35), Virus-based gene therapy research(29)

Publications350 total

Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study
Clinical Cancer Research·2026
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.
2026Open Access
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
Nature Medicine·2026
Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers
Molecular Therapy·2026
Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor
Molecular Therapy·2026
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Outcomes of relapse after teclistamab therapy in multiple myeloma
Blood Cancer Journal·2025Open Access
page 1 of 18Next →

Frequent Co-authors

Carl H. June(33), Simon F. Lacey(18), J. Joseph Melenhorst(18), Megan M. Davis(17), Bruce L. Levine(17), Gabriela Plesa(15), Wei‐Ting Hwang(12), Julie K. Jadlowsky(11), Elizabeth O. Hexner(11), Regina M. Young(10), Irina Kulikovskaya(10), David L. Porter(10), John Scholler(10), Marco Ruella(10), Jun Xu(9), Donald L. Siegel(9), Michael C. Milone(9), Saar Gill(9), Marcela V. Maus(9), Noelle V. Frey(8)